Mutations in type 1 procollagen that cause osteogenesis imperfecta: effects of the mutations on the assembly of collagen into fibrils, the basis of phenotypic variations, and potential antisense therapies - PubMed (original) (raw)
Review
. 1993 Dec:8 Suppl 2:S489-92.
doi: 10.1002/jbmr.5650081311.
Affiliations
- PMID: 8122517
- DOI: 10.1002/jbmr.5650081311
Review
Mutations in type 1 procollagen that cause osteogenesis imperfecta: effects of the mutations on the assembly of collagen into fibrils, the basis of phenotypic variations, and potential antisense therapies
D J Prockop et al. J Bone Miner Res. 1993 Dec.
Abstract
Work by a large number of investigators over the last decade has established that over 90% of patients with osteogenesis imperfecta have mutations in one of the two genes for type I procollagen, that most unrelated probands have different mutations in the genes, and that the mutations found in most of the serious variants of the disease cause synthesis of abnormal pro alpha chains of the protein. The results have demonstrated that synthesis of structurally abnormal but partially functional pro alpha chains can interfere with folding of the central region of the protein into a triple-helical conformation, prevent processing of the N-terminal propeptides of procollagen, or produce subtle alterations in conformation that interfere with the self-assembly of the protein into collagen fibrils. One of the unsolved mysteries about the disease is why some mutations produce severe phenotypes, whereas very similar mutations produce mild phenotypes. Recent studies in transgenic mice suggest that nongenetic factors, such as stochastic events during development, may determine the severity of the disease phenotype produced by a specific mutation. Also, recent results raised the possibility that strategies of antisense gene therapy may be effective in treating the disease some time in the future. Specific inhibition of expression of a mutated collagen gene has been obtained with antisense oligonucleotides in cell culture experiments. However, there is no means of selective delivery of antisense oligonucleotides to the appropriate tissues.
Similar articles
- Type I procollagen: the gene-protein system that harbors most of the mutations causing osteogenesis imperfecta and probably more common heritable disorders of connective tissue.
Prockop DJ, Constantinou CD, Dombrowski KE, Hojima Y, Kadler KE, Kuivaniemi H, Tromp G, Vogel BE. Prockop DJ, et al. Am J Med Genet. 1989 Sep;34(1):60-7. doi: 10.1002/ajmg.1320340112. Am J Med Genet. 1989. PMID: 2683782 Review. - Molecular basis of osteogenesis imperfecta and related disorders of bone.
Prockop DJ, Kuivaniemi H, Tromp G. Prockop DJ, et al. Clin Plast Surg. 1994 Jul;21(3):407-13. Clin Plast Surg. 1994. PMID: 7924138 Review. - Bone fragility in transgenic mice expressing a mutated gene for type I procollagen (COL1A1) parallels the age-dependent phenotype of human osteogenesis imperfecta.
Pereira RF, Hume EL, Halford KW, Prockop DJ. Pereira RF, et al. J Bone Miner Res. 1995 Dec;10(12):1837-43. doi: 10.1002/jbmr.5650101202. J Bone Miner Res. 1995. PMID: 8619363 - Mutations in type I collagen genes resulting in osteogenesis imperfecta in humans.
Gajko-Galicka A. Gajko-Galicka A. Acta Biochim Pol. 2002;49(2):433-41. Acta Biochim Pol. 2002. PMID: 12362985 Review. - Molecular heterogeneity in osteogenesis imperfecta type I.
Willing MC, Pruchno CJ, Byers PH. Willing MC, et al. Am J Med Genet. 1993 Jan 15;45(2):223-7. doi: 10.1002/ajmg.1320450214. Am J Med Genet. 1993. PMID: 8456806
Cited by
- Analysis of miRNAs in Osteogenesis imperfecta Caused by Mutations in COL1A1 and COL1A2: Insights into Molecular Mechanisms and Potential Therapeutic Targets.
Botor M, Auguściak-Duma A, Lesiak M, Sieroń Ł, Dziedzic-Kowalska A, Witecka J, Asman M, Madetko-Talowska A, Bik-Multanowski M, Galicka A, Sieroń AL, Gawron K. Botor M, et al. Pharmaceuticals (Basel). 2023 Oct 4;16(10):1414. doi: 10.3390/ph16101414. Pharmaceuticals (Basel). 2023. PMID: 37895885 Free PMC article. - Dissecting the phenotypic variability of osteogenesis imperfecta.
Garibaldi N, Besio R, Dalgleish R, Villani S, Barnes AM, Marini JC, Forlino A. Garibaldi N, et al. Dis Model Mech. 2022 May 1;15(5):dmm049398. doi: 10.1242/dmm.049398. Epub 2022 May 16. Dis Model Mech. 2022. PMID: 35575034 Free PMC article. - Potential Role of Lycopene in the Prevention of Postmenopausal Bone Loss: Evidence from Molecular to Clinical Studies.
Walallawita US, Wolber FM, Ziv-Gal A, Kruger MC, Heyes JA. Walallawita US, et al. Int J Mol Sci. 2020 Sep 27;21(19):7119. doi: 10.3390/ijms21197119. Int J Mol Sci. 2020. PMID: 32992481 Free PMC article. Review. - Heart valve development: regulatory networks in development and disease.
Combs MD, Yutzey KE. Combs MD, et al. Circ Res. 2009 Aug 28;105(5):408-21. doi: 10.1161/CIRCRESAHA.109.201566. Circ Res. 2009. PMID: 19713546 Free PMC article. Review. - Consortium for osteogenesis imperfecta mutations in the helical domain of type I collagen: regions rich in lethal mutations align with collagen binding sites for integrins and proteoglycans.
Marini JC, Forlino A, Cabral WA, Barnes AM, San Antonio JD, Milgrom S, Hyland JC, Körkkö J, Prockop DJ, De Paepe A, Coucke P, Symoens S, Glorieux FH, Roughley PJ, Lund AM, Kuurila-Svahn K, Hartikka H, Cohn DH, Krakow D, Mottes M, Schwarze U, Chen D, Yang K, Kuslich C, Troendle J, Dalgleish R, Byers PH. Marini JC, et al. Hum Mutat. 2007 Mar;28(3):209-21. doi: 10.1002/humu.20429. Hum Mutat. 2007. PMID: 17078022 Free PMC article. Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical